TICKERNERD
Menu
RGCRGCHealthcare · Drug Manufacturers - Specialty & Generic

RGC Stock Forecast: Regencell Bioscience Holdings Ltd. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$5.32
−2.21% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 4 of 100 as at 21 Aug 2026 — in the weakest quartile.

Market cap
$2.6B
Ticker Nerd rank
4 / 100
Median analyst target
—
Analysts covering
15
Total return, dividends reinvested
1W
−2.4%
1M
−12.2%
YTD
−74.7%
1Y
−57.6%
From 52W high
−89.9%
From 52W low
+11.3%
$5
$53
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RGC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Regencell Bioscience Holdings Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Aug 2026
4 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
35
Volatility
34
Issuance
34
Size
33
Revisions
25
Accruals
17
Value
15
Momentum
13
Quality
6

Growth (35): Sales and profits are climbing, and climbing faster than before.

Quality (6): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RGC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RGC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26RGC

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says15 analysts
9 Buy5 Hold1 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 Dec 2017MacquarieDowngradeNeutral—
6 Dec 2017MoffettNathansonUpgradeNeutral—
6 Dec 2017RBC CapitalDowngradeSector Perform—
5 Dec 2017WedbushDowngradeNeutral—
26 Oct 2017RBC CapitalUpgradeOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RGC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

RGC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Regencell Bioscience Holdings Ltd. (RGC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−740.3×

Cheaper than 99% of US stocks

Price / sales
—
Price / book
2650.0×

Cheaper than 1% of US stocks

EV / EBITDA
−370.6×

Cheaper than 99% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−177.7%

Higher than 8% of US stocks

Return on assets
−85.0%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

RGC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
RGCRegencell Bioscience Holdings Ltd.$2.6B
4
SUPNSupernus Pharmaceuticals, Inc.$2.6B
84
PBHPrestige Consumer Healthcare, Inc.$2.5B
59
BCRXBioCryst Pharmaceuticals, Inc.$2.4B
87
BHCBausch Health Cos., Inc.$2.4B
96
TRLVTrulieve Cannabis Corp.$2.1B
87
PRGOPerrigo Co. Plc$2.0B
69

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Regencell Bioscience Holdings Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RGC news & analysis

RGC Resources: More Likely To Appeal More To Income-Focused Investors

Seeking Alpha · 18 Aug 2026neutral

Seeking Alpha published an analysis of RGC Resources, a micro-cap natural gas utility with limited growth prospects and a small, stable service area. The article notes sluggish earnings growth, with FY 2026 guidance implying just 1.2% year-over-year EPS growth, and highlights a 4.04% forward dividend yield supported by an 82-year dividend history.

Why it matters — RGC watchers would care because the piece frames the company as primarily appealing to income-focused investors given its long dividend history, while acknowledging its limited growth outlook.

FAQ

Frequently asked questions about RGC stock

Is RGC stock a buy right now?

Of the 15 analysts covering Regencell Bioscience Holdings Ltd., 9 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Regencell Bioscience Holdings Ltd. 4 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RGC?

As at 21 Aug 2026, Regencell Bioscience Holdings Ltd. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (35 of 100).

What is the RGC stock forecast for 2030?

No analyst covering Regencell Bioscience Holdings Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RGC are extrapolating price history, which says nothing about the business.

How has RGC stock performed over the past year?

Regencell Bioscience Holdings Ltd. returned -57.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Regencell Bioscience Holdings Ltd. do?

Regencell Bioscience Holdings Ltd. is a bioscience company specializing in the research, development, and commercialization of Traditional Chinese Medicine (TCM) formulations.

What is the latest news on RGC?

The most recent item we track (Seeking Alpha, 18 Aug 2026): "RGC Resources: More Likely To Appeal More To Income-Focused Investors". Seeking Alpha published an analysis of RGC Resources, a micro-cap natural gas utility with limited growth prospects and a small, stable service area. The article notes sluggish earnings growth, with FY 2026 guidance implying just 1.2% year-over-year EPS growth, and highlights a 4.04% forward dividend yield supported by an 82-year dividend history.

Company

About Regencell Bioscience Holdings Ltd.

Regencell Bioscience Holdings Ltd. is a bioscience company specializing in the research, development, and commercialization of Traditional Chinese Medicine (TCM) formulations. It targets neurocognitive disorders and degenerations, with a primary focus on Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD), as well as infectious diseases that impact the immune system. The company develops natural formulas aimed at treating these conditions, emphasizing innovative approaches within the healthcare sector. Through its subsidiary Regencell Limited, incorporated in Hong Kong, it conducts operations from its headquarters in Causeway Bay, Hong Kong. Regencell Bioscience Holdings Ltd. also supports community initiatives via the Regencell Foundation, established in 2017, which provides assistance to children with ADHD and ASD, and elderly individuals with dementia facing financial challenges. This positions the company as an active player in advancing TCM-based therapies for prevalent neurological and immunological health issues, serving patients, families, caregivers, and medical professionals seeking alternative treatments.

CEO Mr. Yat-Gai Au · 10 employees · Hong Kong · https://www.regencellbioscience.com